Kiora Pharmaceuticals
KPRX
19 hedge funds and large institutions have $1.34M invested in Kiora Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
12% more funds holding
Funds holding: 17 → 19 (+2)
48.38% less ownership
Funds ownership: 53.11% → 4.73% (-48%)
92% less capital inflows, than outflows
Capital inflows: $1M | Capital outflows: $13.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$526K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$122K |
| 3 |
Jane Street
New York
|
+$82.4K |
| 4 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
+$58.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$12.2M |
| 2 |
Renaissance Technologies
New York
|
-$328K |
| 3 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$275K |
| 4 |
Two Sigma Advisers
New York
|
-$139K |
| 5 |
Two Sigma Investments
New York
|
-$99K |
KPRX Hedge Fund Activity: Q3 2021 in Review
19 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2021, worth a combined $1.34M — down 90% from $13.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KPRX positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $526K. The largest seller was Armistice Capital, exiting entirely with an estimated $12.2M sold.
- 19 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2021, up from 17 in Q2 2021.
- Funds reported $1.34M of Kiora Pharmaceuticals stock for Q3 2021, down 90% quarter-over-quarter.
- 8 funds opened new Kiora Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2021 was Geode Capital Management, an estimated $526K added.
- The largest Kiora Pharmaceuticals seller in Q3 2021 was Armistice Capital, an estimated $12.2M sold.
Based on aggregated 13F filings for Q3 2021.